```html

Fahr’s Disease – Comprehensive Medical Guide

Overview

Fahr’s disease, also known as primary familial brain calcification (PFBC), is a rare, progressive neurological disorder characterized by abnormal calcium deposits (calcifications) in the basal ganglia and other brain regions. The condition can be hereditary (autosomal dominant) or occur sporadically without a clear family history.

Typical age of onset ranges from the second to the sixth decade of life, but cases have been reported in children and the elderly. The disease affects men and women equally.

Prevalence is difficult to determine because many individuals are asymptomatic and discovered incidentally on brain imaging. Epidemiologic studies estimate a prevalence of roughly 0.5–1 per 1,000,000 people worldwide, though some screening studies in specific populations suggest higher rates (up to 1 in 20,000).<sup>[1] Mayo Clinic</sup>

Symptoms

Symptoms are highly variable and may evolve slowly over years. They can be grouped into motor, neuropsychiatric, cognitive, and systemic categories.

Motor and Coordination Problems

• Parkinsonism: Tremor, rigidity, bradykinesia, and postural instability similar to Parkinson disease.
• Dystonia: Involuntary muscle contractions causing abnormal postures.
• Ataxia: Unsteady gait and clumsiness due to cerebellar involvement.
• Seizures: Focal or generalized seizures in up to 30% of patients.<sup>[2] NIH</sup>

Neuropsychiatric Symptoms

• Psychosis: Hallucinations, delusions, or paranoid ideation.
• Depression & Anxiety: Mood changes are common and may precede motor signs.
• Personality changes: Irritability, apathy, or disinhibition.

Cognitive Impairment

• Mild cognitive decline: Difficulty with attention, executive function, and memory.
• Dementia: In advanced cases, a frontotemporal‑like dementia can develop.

Other Neurologic Findings

• Headache
• Vertigo or dizziness
• Speech difficulties (dysarthria)
• Vision changes (rare)

Because the disease can be silent, many individuals are first diagnosed after an unrelated head CT or MRI shows calcifications.

Causes and Risk Factors

Fahr’s disease is primarily linked to genetic mutations that affect calcium metabolism in the brain.

Genetic Causes

• SLC20A2 – most common (≈ 30–40% of familial cases).
• PDGFB and PDGFRB – encode platelet‑derived growth factor ligands/receptors.
• XPR1 – involved in phosphate export.
• Other rare genes: MYORG, JAM2, ZNF ...

These genes regulate phosphate transport and vascular integrity; their disruption leads to calcium‑phosphate precipitation in perivascular spaces.

Non‑Genetic (Secondary) Causes

Calcifications similar to those seen in Fahr’s disease may occur secondary to:

• Metabolic disorders – hypoparathyroidism, hyperparathyroidism, vitamin D deficiency.
• Infections – TORCH, HIV, neurocysticercosis.
• Toxic exposures – lead, aluminum.
• Traumatic brain injury.

Risk Factors

• Family history of PFBC (autosomal‑dominant inheritance).
• Known pathogenic mutations in the genes listed above.
• Chronic calcium/phosphate metabolic abnormalities.

Diagnosis

Diagnosis requires a combination of clinical assessment, neuroimaging, and exclusion of secondary causes.

Clinical Evaluation

• Detailed history: symptom chronology, family history of similar disorders, endocrine problems.
• Neurologic examination focusing on movement, gait, reflexes, and cognitive testing.

Neuroimaging

• CT scan (non‑contrast): The gold standard for detecting calcifications. Typical finding – symmetric, bilateral hyperdensities in the basal ganglia (especially globus pallidus), thalamus, dentate nuclei, and subcortical white matter.
• MRI: Useful for assessing associated gliosis or vascular changes; calcifications appear dark on susceptibility‑weighted imaging (SWI).
• Quantitative CT scoring systems have been proposed to grade disease burden.

Laboratory Tests (to rule out secondary causes)

• Serum calcium, phosphate, magnesium.
• Parathyroid hormone (PTH) level.
• Vitamin D (25‑OH) level.
• Renal function tests (creatinine, eGFR).
• Screen for infectious agents if clinically indicated.

Genetic Testing

If familial disease is suspected, next‑generation sequencing panels that include SLC20A2, PDGFB, PDGFRB, XPR1, MYORG and others are recommended. Confirmation of a pathogenic variant confirms a diagnosis of primary familial brain calcification.

Diagnostic Criteria (simplified)

1. Bilaterally symmetrical calcifications in basal ganglia (or other typical regions) on CT.
2. Absence of metabolic, infectious, or toxic causes after appropriate labs.
3. Either a pathogenic gene mutation or a first‑degree relative with the same imaging pattern.

Treatment Options

There is currently no cure that removes existing calcifications. Management focuses on symptom control, slowing progression, and addressing reversible metabolic abnormalities.

Medication

• Parkinsonism: Levodopa/carbidopa can improve tremor and rigidity in some patients, although response is variable.
• Seizure control: Standard antiepileptic drugs (e.g., levetiracetam, lamotrigine) are used as indicated.
• Psychiatric symptoms: SSRIs for depression; atypical antipsychotics (risperidone, quetiapine) for psychosis, with careful monitoring for extrapyramidal side effects.
• Behavioral/cognitive issues: Cholinesterase inhibitors (donepezil) have anecdotal benefit in some cases of dementia.

Addressing Metabolic Contributors

If laboratory work uncovers hypoparathyroidism, hyperparathyroidism, or vitamin D deficiency, endocrine treatment (calcium supplementation, active vitamin D analogues, or surgical parathyroidectomy) may reduce further calcification, though evidence for reversal is limited.<sup>[3] Cleveland Clinic</sup>

Procedural Interventions

• Deep Brain Stimulation (DBS): Pilot reports suggest DBS of the globus pallidus interna can alleviate severe parkinsonian features refractory to medication; however, data are scarce.
• Surgical removal: Not feasible because calcifications are diffuse and intra‑parenchymal.

Lifestyle and Supportive Therapies

• Physical therapy to maintain balance, strength, and gait.
• Occupational therapy for fine‑motor tasks and ADL adaptations.
• Speech therapy for dysarthria.
• Regular psychiatric counseling or support groups.

Living with Fahr’s Disease

Adapting to the progressive nature of the disease can improve quality of life.

Daily Management Tips

• Medication adherence: Use pill organizers or reminder apps.
• Fall prevention: Remove loose rugs, install grab bars, ensure good lighting, and use a cane or walker when needed.
• Regular exercise: Low‑impact activities (walking, swimming, tai chi) help maintain motor function and mood.
• Cognitive stimulation: Puzzles, reading, or computer‑based brain games can slow cognitive decline.
• Nutrition: Balanced diet rich in calcium‑binding foods (leafy greens) while avoiding excessive calcium supplements unless prescribed.
• Monitor mood: Keep a journal of mood changes; discuss new or worsening symptoms with your neurologist promptly.

Family & Caregiver Guidance

• Educate relatives about the unpredictable course of symptoms.
• Plan for eventual need of caregiving assistance (home health aide, respite care).
• Consider legal planning early—advance directives, power of attorney.

Support Resources

• Fahr Disease Foundation (www.fahrdisease.org) – patient advocacy, research updates.
• National Organization for Rare Disorders (NORD).
• Local neurology or movement‑disorder support groups.

Prevention

Because the primary form is genetic, primary prevention is limited. However, secondary prevention—avoiding exacerbating metabolic disturbances—can be valuable.

• Maintain normal calcium/phosphate balance: Regular labs if you have a known mutation.
• Treat endocrine disorders promptly: Hypo‑ or hyperparathyroidism correction.
• Avoid toxic exposures: Lead, aluminum, and certain occupational chemicals.
• Healthy lifestyle: Regular exercise, adequate sleep, and stress management may reduce the impact of neuropsychiatric symptoms.

Complications

If untreated or inadequately managed, Fahr’s disease can lead to:

• Progressive disability due to severe parkinsonism or ataxia.
• Recurrent, uncontrolled seizures.
• Psychiatric crises (violent behavior, severe depression, suicidal ideation).
• Falls and resultant fractures, particularly hip fractures in older adults.
• Institutionalization due to loss of independence.

When to Seek Emergency Care

Prompt evaluation can prevent permanent injury and allow rapid treatment adjustments.

---

References:

1. Mayo Clinic. “Fahr disease (brain calcification).” Accessed March 2024. https://www.mayoclinic.org
2. National Institute of Neurological Disorders and Stroke. “Primary Familial Brain Calcification (Fahr Disease).” Updated 2023. https://www.ninds.nih.gov
3. Cleveland Clinic. “Calcification of the Basal Ganglia.” 2022. https://my.clevelandclinic.org
4. World Health Organization. “Rare Diseases: An Introduction.” 2021.
5. Fahr Disease Foundation. Clinical Guidelines 2023.

```